SLC5A2 and type 1 diabetes mellitus: Although sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrate partial efficacy in preserving target organs and improving glycemia, their use in T1D patients is associated with a higher incidence of adverse events (AEs) (3), particularly diabetic ketoacidosis (DKA), which contributes to elevated mortality rates in T1D (4, 5).